Cargando…

The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020

BACKGROUND AND OBJECTIVES: Human immunodeficiency virus (HIV) has various transmission routes. Instant antiretroviral therapy (ART) is the recommended treatment for HIV infection. Highly active antiretroviral therapy (HAART) significantly decreases the acquired immunodeficiency syndrome (AIDS) and A...

Descripción completa

Detalles Bibliográficos
Autores principales: Garshasbi, Saba, Marjani, Arezoo, Alipour, Ali, Khanaliha, Khadijeh, Esghaei, Maryam, Fakhim, Atousa, Bokharaei-Salim, Farah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816700/
https://www.ncbi.nlm.nih.gov/pubmed/35222867
http://dx.doi.org/10.18502/ijm.v13i6.8094
_version_ 1784645492006715392
author Garshasbi, Saba
Marjani, Arezoo
Alipour, Ali
Khanaliha, Khadijeh
Esghaei, Maryam
Fakhim, Atousa
Bokharaei-Salim, Farah
author_facet Garshasbi, Saba
Marjani, Arezoo
Alipour, Ali
Khanaliha, Khadijeh
Esghaei, Maryam
Fakhim, Atousa
Bokharaei-Salim, Farah
author_sort Garshasbi, Saba
collection PubMed
description BACKGROUND AND OBJECTIVES: Human immunodeficiency virus (HIV) has various transmission routes. Instant antiretroviral therapy (ART) is the recommended treatment for HIV infection. Highly active antiretroviral therapy (HAART) significantly decreases the acquired immunodeficiency syndrome (AIDS) and AIDS-related co-morbidities. Notwithstanding the suitability of HAART, the antiretrovirals (ARVs) have adverse effects and antiretroviral drug resistance mutations are reported among those who receive ARVs. In this survey, the abundance of HIV-1 infection in Iranians with high-risk behaviors, and detection of the surveillance drug-resistant mutations (SDRMs) were evaluated. MATERIALS AND METHODS: This cross-sectional study was conducted on 250 individuals with high-risk behaviors from September 2014 to February 2020. HIV-1 Ag/Ab in plasma samples was detected using enzyme immunoassay (EIA) kits. The conserved region of HIV-1 was detected in the plasma samples by real-time polymerase chain reaction (PCR) assay. Furthermore, in individuals with positive HIV-1 RNA, HIV-1 viral load testing was performed. After amplification and sequencing of the HIV-1 protease, reverse transcriptase, and integrase genes, surveillance drug resistance mutation (SDRM) and phylogenetic analysis were determined. RESULTS: Out of the 250 participants with high-risk behaviors, six (2.4%) were infected with HIV-1. According to the phylogenetic analysis, the CRF35_AD (83.3% or 5/6) was the dominant subtype, followed by CRF01_AE (16.7% or 1/6). In this research, in none of the HIV-1 infected patients, SDRM for protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase inhibitors (INs) were observed. Nevertheless, in one of the patients, V179L mutation was detected which is a rare non-polymorphic mutation and is listed as a rilpivirine (RPV) -associated resistance mutation. CONCLUSION: The results of the current survey revealed that 2.4% of people with high-risk behaviors are infected with HIV and the level of drug resistance mutations (DRMs) in these people is very low.
format Online
Article
Text
id pubmed-8816700
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-88167002022-02-25 The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020 Garshasbi, Saba Marjani, Arezoo Alipour, Ali Khanaliha, Khadijeh Esghaei, Maryam Fakhim, Atousa Bokharaei-Salim, Farah Iran J Microbiol Original Article BACKGROUND AND OBJECTIVES: Human immunodeficiency virus (HIV) has various transmission routes. Instant antiretroviral therapy (ART) is the recommended treatment for HIV infection. Highly active antiretroviral therapy (HAART) significantly decreases the acquired immunodeficiency syndrome (AIDS) and AIDS-related co-morbidities. Notwithstanding the suitability of HAART, the antiretrovirals (ARVs) have adverse effects and antiretroviral drug resistance mutations are reported among those who receive ARVs. In this survey, the abundance of HIV-1 infection in Iranians with high-risk behaviors, and detection of the surveillance drug-resistant mutations (SDRMs) were evaluated. MATERIALS AND METHODS: This cross-sectional study was conducted on 250 individuals with high-risk behaviors from September 2014 to February 2020. HIV-1 Ag/Ab in plasma samples was detected using enzyme immunoassay (EIA) kits. The conserved region of HIV-1 was detected in the plasma samples by real-time polymerase chain reaction (PCR) assay. Furthermore, in individuals with positive HIV-1 RNA, HIV-1 viral load testing was performed. After amplification and sequencing of the HIV-1 protease, reverse transcriptase, and integrase genes, surveillance drug resistance mutation (SDRM) and phylogenetic analysis were determined. RESULTS: Out of the 250 participants with high-risk behaviors, six (2.4%) were infected with HIV-1. According to the phylogenetic analysis, the CRF35_AD (83.3% or 5/6) was the dominant subtype, followed by CRF01_AE (16.7% or 1/6). In this research, in none of the HIV-1 infected patients, SDRM for protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase inhibitors (INs) were observed. Nevertheless, in one of the patients, V179L mutation was detected which is a rare non-polymorphic mutation and is listed as a rilpivirine (RPV) -associated resistance mutation. CONCLUSION: The results of the current survey revealed that 2.4% of people with high-risk behaviors are infected with HIV and the level of drug resistance mutations (DRMs) in these people is very low. Tehran University of Medical Sciences 2021-12 /pmc/articles/PMC8816700/ /pubmed/35222867 http://dx.doi.org/10.18502/ijm.v13i6.8094 Text en Copyright © 2021 The Authors. Published by Tehran University of Medical Sciences https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Garshasbi, Saba
Marjani, Arezoo
Alipour, Ali
Khanaliha, Khadijeh
Esghaei, Maryam
Fakhim, Atousa
Bokharaei-Salim, Farah
The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020
title The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020
title_full The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020
title_fullStr The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020
title_full_unstemmed The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020
title_short The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020
title_sort frequency of hiv-1 infection and surveillance drug-resistant mutations determination among iranians with high-risk behaviors, during 2014 to 2020
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816700/
https://www.ncbi.nlm.nih.gov/pubmed/35222867
http://dx.doi.org/10.18502/ijm.v13i6.8094
work_keys_str_mv AT garshasbisaba thefrequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT marjaniarezoo thefrequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT alipourali thefrequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT khanalihakhadijeh thefrequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT esghaeimaryam thefrequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT fakhimatousa thefrequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT bokharaeisalimfarah thefrequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT garshasbisaba frequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT marjaniarezoo frequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT alipourali frequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT khanalihakhadijeh frequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT esghaeimaryam frequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT fakhimatousa frequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020
AT bokharaeisalimfarah frequencyofhiv1infectionandsurveillancedrugresistantmutationsdeterminationamongiranianswithhighriskbehaviorsduring2014to2020